Asia-Pacific Cardiovascular Therapeutic Drugs Market by disease (Arteriosclerosis, Cardiac arrhythmias, Myocardial infarction, acute coronary syndrome, Peripheral artery disease, Coronary artery disease, hypertension, hyperlipidaemia, thrombosis, cardiac failure diseases and other cardiovascular diseases), by drug class (monotherapies and combination) and by Region – Industry Analysis, Size, Share, Growth, Trends, and Forecast (2016 – 2021)

Asia-Pacific Cardiovascular Therapeutic Drugs Market by disease (Arteriosclerosis, Cardiac arrhythmias, Myocardial infarction, acute coronary syndrome, Peripheral artery disease, Coronary artery disease, hypertension, hyperlipidaemia, thrombosis, cardiac failure diseases and other cardiovascular diseases), by drug class (monotherapies and combination) and by Region – Industry Analysis, Size, Share, Growth, Trends, and Forecast (2016 – 2021)

ID: 1429 | Pages: 121 | November 2016 | Region: Asia Pacific


Asia-Pacific Cardiovascular Therapeutic Drugs is a USD 26.63 billion market in 2016 and is projected to reach USD 30.27 billion by 2021 growing with a cumulative annual growth rate (CAGR) of 2.6%. Several new and effective drug therapies for cardiovascular disorders have been development in the past few decades. With the rising prevalence of cardiovascular diseases, the market for therapeutics drugs is likely to grow in the future.

Cardiovascular drugs includes medicines or drugs that are administered for the diseases that are related to the function and structure of blood vessels and heart. While cardiovascular disorders continues to be leading cause of death globally, the major disorders includes heart failure, high cholesterol, coronary artery disease and blood clots among others.

Cardiovascular diseases remains the common cause of mortality and morbidity across the globe and is an emerging threat. The driving factors for the cardiovascular therapeutics includes growing per capita medical spending, rising aging population and epidemic of general medical problems which includes obesity and diabetes. However, there are few restraints faced by the market which includes high costs involving drug development and lowering of target population. Cardiovascular diseases remains the common cause of mortality and morbidity across the globe and is an emerging threat. Despite its extensive existence, many of the drug development pipelines has been stagnant for variety of factors.

Asia-Pacific market for cardiovascular therapeutic drugs market is segmented into diseases and drug class. Based on the type of cardiovascular diseases, the market is studied as hypertension, thrombosis, hyperlipidaemia, Arteriosclerosis, Coronary artery disease, Peripheral artery disease, Cardiac arrhythmias, acute coronary syndrome, Myocardial infarction, cardiac failure diseases and other diseases. Asia-Pacific market based on its geographical regions, is segmented into China, Japan, India, South Korea and Australia.

Some of the major companies leading in the industry includes Bayer, Johnson & Johnson, AstraZeneca, Bristol-Myers Squibb, Novartis, Merck, Takeda, Sanofi, Pfizer and boehringer ingelheim.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 New Developments                

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Disease                  

                                5.1.1 Arteriosclerosis     

                                5.1.2 Cardiac arrhythmias            

                                5.1.3 Myocardial infarction         

                                5.1.4 Acute Coronary Syndrome

                                5.1.5 Peripheral artery disease  

                                5.1.6 Coronary artery disease    

                                5.1.7 Hypertension        

                                5.1.8 Hyperlipidaemia   

                                5.1.9 Thrombosis            

                                5.1.10 Cardiac failure diseases  

                                5.1.11 Others   

                5.2 By Drug Class                             

                                5.2.1 Monotherapies     

                                5.2.2 Combination Therapies     

6. Geographical Analysis                                              

                6.1 Introduction                              

                6.2 China                            

                6.3 India                              

                6.4 Japan                            

                6.5 South Korea               

                6.6 Australia                      

7. Pipeline Product Analysis                                        

                7.1 Overview                                    

                7.2 Pipeline Development Landscape                                     

                7.3 Molecular Targets in the Pipeline                                     

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                 

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.               

8. Strategic Analysis                                       

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9. Market Leaders' Analysis                                        

                9.1 AstraZeneca               

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Strategic Evaluation and Operations            

                                9.1.4 Financial analysis  

                                9.1.5 Legal issues            

                                9.1.6 Recent Developments       

                                9.1.7 SWOT analysis       

                                9.1.8 Analyst View          

                9.2 Novartis                       

                9.3 Bristol-Myers Squibb                              

                9.4 Pfizer                            

                9.5 Sanofi                           

                9.6 Merck                           

                9.7 Bayer                            

                9.8 Takeda                         

                9.9 Boehringer Ingelheim                            

                9.10 Johnson & Johnson                              

10. Competitive Landscape                                         

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                       

                10.4 New Product Launches                       

11. Expert Opinions                                        

                11.1 Market Outlook                     

                11.2 Investment Opportunities                 

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
TitlePriceAdd To Cart
  1. Asia-Pacific Cardiovascular Therapeutic Drugs Market By Region, From 2016-2020 (USD Million)                                                 
  2. Asia-Pacific Cardiovascular Therapeutic Drugs Market By Disease, From 2016-2020 (USD Million)                                                
  3. Asia-Pacific Arteriosclerosis Market By Region, From 2016-2020 (USD Million)                                                     
  4. Asia-Pacific Cardiac arrhythmias Market By Region, From 2016-2020 (USD Million)                                                            
  5. Asia-Pacific Myocardial infarction Market By Region, From 2016-2020 (USD Million)                                                          
  6. Asia-Pacific Acute Coronary Syndrome Market By Region, From 2016-2020 (USD Million)                                                
  7. Asia-Pacific Peripheral artery disease Market By Region, From 2016-2020 (USD Million)                                                   
  8. Asia-Pacific Coronary artery disease Market By Region, From 2016-2020 (USD Million)                                                     
  9. Asia-Pacific Hypertension Market By Region, From 2016-2020 (USD Million)                                                         
  10. Asia-Pacific Hyperlipidaemia Market By Region, From 2016-2020 (USD Million)                                                    
  11. Asia-Pacific Thrombosis Market By Region, From 2016-2020 (USD Million)                                                             
  12. Asia-Pacific Cardiac failure diseases Market By Region, From 2016-2020 (USD Million)                                                      
  13. Asia-Pacific Cardiovascular Therapeutic Drugs Market By Drug Class, From 2016-2020 (USD Million)                                                           
  14. Asia-Pacific Monotherapies Market By Region, From 2016-2020 (USD Million)                                                      
  15. Asia-Pacific Combination Therapies Market By Region, From 2016-2020 (USD Million)                                                      
  16. China Cardiovascular Therapeutic Drugs Market By Disease, From 2016-2020 (USD Million)                                                           
  17. China Cardiovascular Therapeutic Drugs Market By Drug Class, From 2016-2020 (USD Million)                                                      
  18. India Cardiovascular Therapeutic Drugs Market By Disease, From 2016-2020 (USD Million)                                                             
  19. India Cardiovascular Therapeutic Drugs Market By Drug Class, From 2016-2020 (USD Million)                                                       
  20. Japan Cardiovascular Therapeutic Drugs Market By Disease, From 2016-2020 (USD Million)                                                           
  21. Japan Cardiovascular Therapeutic Drugs Market By Drug Class, From 2016-2020 (USD Million)                                                      
  22. South Korea Cardiovascular Therapeutic Drugs Market By Disease, From 2016-2020 (USD Million)                                                              
  23. South Korea Cardiovascular Therapeutic Drugs Market By Drug Class, From 2016-2020 (USD Million)                                                         
  24. Australia Cardiovascular Therapeutic Drugs Market By Disease, From 2016-2020 (USD Million)                                                     
  25. Australia Cardiovascular Therapeutic Drugs Market By Drug Class, From 2016-2020 (USD Million)                                               
Middle East And Africa Psychiatry Therapies Market By Type (Social Psychology, Abnormal Psychology, Biological Psychology And Other Types), By Type Of Medication (Antidepressants, Antipsychotics, Depressants, Anxiol...
Latin America Psychiatry Therapies Market By Type (Social Psychology, Abnormal Psychology, Biological Psychology And Other Types), By Type Of Medication (Antidepressants, Antipsychotics, Depressants, Anxiolytics, Mo...
Asia Pacific Psychiatry Therapies Market By Type (Social Psychology, Abnormal Psychology, Biological Psychology And Other Types), By Type Of Medication (Antidepressants, Antipsychotics, Depressants, Anxiolytics, Moo...
Europe Psychiatry Therapies Market By Type (Social Psychology, Abnormal Psychology, Biological Psychology And Other Types), By Type Of Medication (Antidepressants, Antipsychotics, Depressants, Anxiolytics, Mood Stab...
North America Psychiatry Therapies Market By Type (Social Psychology, Abnormal Psychology, Biological Psychology And Other Types), By Type Of Medication (Antidepressants, Antipsychotics, Depressants, Anxiolytics, Mo...
Psychiatry Therapies Market By Type (Social Psychology, Abnormal Psychology, Biological Psychology And Other Types), By Type Of Medication (Antidepressants, Antipsychotics, Depressants, Anxiolytics, Mood Stabilisers...
Middle East and Africa Home Healthcare Market by Product (Testing, Screening, & Monitoring Products, Therapeutic Products, Mobility Care Products) by Service (Rehabilitation Therapy Services, Infusion Therapy Servic...
Latin America Home Healthcare Market by Product (Testing, Screening, & Monitoring Products, Therapeutic Products, Mobility Care Products) by Service (Rehabilitation Therapy Services, Infusion Therapy Services, Unski...
Asia-Pacific Home Healthcare Market by Product (Testing, Screening, & Monitoring Products, Therapeutic Products, Mobility Care Products) by Service (Rehabilitation Therapy Services, Infusion Therapy Services, Unskil...
Europe Home Healthcare Market by Product (Testing, Screening, & Monitoring Products, Therapeutic Products, Mobility Care Products) by Service (Rehabilitation Therapy Services, Infusion Therapy Services, Unskilled Ca...
North America Home Healthcare Market by Product (Testing, Screening, & Monitoring Products, Therapeutic Products, Mobility Care Products) by Service (Rehabilitation Therapy Services, Infusion Therapy Services, Unski...
Home Healthcare Market by Product (Mobility Care Products ,Screening, & Monitoring Products, Testing, Therapeutic Products) by Service (Infusion Therapy Services, Rehabilitation Therapy Services, Unskilled Care Serv...

"We Think Through Different Layers, We Work Across Different Verticals."

Market Data Forecast, Inc.
2nd Floor, Lakeview Plaza, Kavuri Hills, Hyderabad, Telangana 500033, India.
+1-888-702-9626 (U.S. TOLL FREE)
contact@marketdataforecast.com


Subscribe To Our News Letter

Or follow us on social platform

© 2017 Market Data Forecast
All Rights Reserved.